Prostate Cancer Clinical Trials in Boston, Massachusetts
59 recruitingBoston, Massachusetts
Showing 1–20 of 59 trials
Recruiting
Phase 2Phase 3
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Prostate Cancer
Novartis Pharmaceuticals443 enrolled72 locationsNCT06780670
Recruiting
Phase 3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled142 locationsNCT05939414
Recruiting
Phase 3
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Prostate CancerAndrogen Axis SuppressionProstatectomy
M.D. Anderson Cancer Center120 enrolled3 locationsNCT06274047
Recruiting
Phase 1
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Urothelial CarcinomaRenal Cell CarcinomaCastration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC60 enrolled4 locationsNCT06966024
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Not Applicable
Video Education With Result Dependent dIsclosure
Breast CancerPancreatic CancerOvarian Cancer+2 more
Dana-Farber Cancer Institute1,020 enrolled1 locationNCT05225428
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Not Applicable
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Prostate Cancer
Varian, a Siemens Healthineers Company132 enrolled7 locationsNCT05804318
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Not Applicable
Stereotactic Magnetic Resonance Guided Radiation Therapy
Prostate CancerLung CancerSpine Metastases+10 more
Dana-Farber Cancer Institute397 enrolled2 locationsNCT04115254
Recruiting
Not Applicable
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
Prostate CancerPolygenic Risk Score
Adam S. Kibel, MD1,500 enrolled5 locationsNCT06398639
Recruiting
Phase 1
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Metastatic Breast CancerAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)+3 more
Olema Pharmaceuticals, Inc.180 enrolled8 locationsNCT06784193
Recruiting
Not Applicable
CV CARE: CardioVascular Care in PC Patients
Prostate CancerCardiovascular Diseases
Dana-Farber Cancer Institute180 enrolled2 locationsNCT06202820
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548
Recruiting
Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Prostate Cancer
University of British Columbia315 enrolled9 locationsNCT04812366
Recruiting
Not Applicable
Comprehensive Outcomes for After Cancer Health
Breast CancerMetastatic Breast CancerGastric Cancer+8 more
Pack Health625 enrolled7 locationsNCT05349227
Recruiting
Not Applicable
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
Prostate CancerUrologic CancerBladder Cancer+5 more
Dana-Farber Cancer Institute10 enrolled1 locationNCT05899361